| Objective: In this study,quantitative polymerase chain reaction(q PCR)was used to detect the expression level of circulating cell-free DNA(cf-DNA)in peripheral blood of patients with multiple myeloma(MM)after initial diagnosis,3 courses of induction chemotherapy and 6 courses of induction chemotherapy,and compare the difference of cf-DNA expression level before and after treatment,so as to evaluate the application value of cf-DNA in evaluating the efficacy of MM.Meanwhile,the correlation between its expression level and clinical features was analyzed.Methods: Patients who were seen at the First Affiliated Hospital of Wannan Medical College between April 2021 and October 2022 and were first diagnosed with MM by bone marrow cytology or pathological histology were collected for the study.37 newly diagnosed MM patients were collected during the period,27 patients completed 3courses of induction chemotherapy,and 14 patients completed 6 courses of induction chemotherapy.The changes of cf-DNA expression level before and after chemotherapy were monitored,and the correlation between cf-DNA expression level and efficacy was analyzed.Results:(1)After 3 courses of treatment,the content and integrity of cf-DNA in remission group were significantly lower than those before treatment(P < 0.05).(2).After 3 courses of treatment,the content of cf-DNA in refractory group was higher than that before treatment(P < 0.05),but the integrity of cf-DNA was lower than that before treatment(P > 0.05).(3)The content of cf-DNA in remission group after 6 treatment courses was lower than that after 3 treatment courses(P < 0.05),and the integrity of cf-DNA in remission group after 6 treatment courses was lower than that after 3treatment courses(P > 0.05).(4)The content of cf-DNA in recurrent or refractory group after 6 treatment courses was higher than that after 3 treatment courses(P < 0.05),and the integrity of cf-DNA in recurrent or refractory group after 6 treatment courses was higher than that after 3 treatment courses(P > 0.05).(5)There was a positive correlation between the content of cf-DNA and the proportion of plasma cells in the bone marrow(P < 0.05),and there was no correlation between the integrity of cf-DNA and the proportion of plasma cells in the bone marrow(P > 0.05).(6)There was no significant difference between the expression level of cf-DNA and age,gender,D-S stage,ISS stage,R-ISS stage,hemoglobin,calcium ion,lactate dehydrogenase,creatinine,albumin,etc.(P > 0.05).Conclusion: 1.The content of cf-DNA in peripheral blood can be used as an effective biomarker to reflect the tumour load of patients with multiple myeloma and to evaluate the efficacy of drugs.2.Regular monitoring of cf-DNA content in peripheral blood can be used as one of the indicators to assess the prognosis of patients with multiple myeloma. |
PDF Full Text Request